StockData
Celularity Inc logo

Celularity Inc (CELU) stock

CELUNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Oct 20, 2026Score 7/30
$0.48−0.09 (-15.41%)

Close on Nov 18, 2026Market cap $15.68MP/E –Yield –

Celularity net income

Net income is the profit left for shareholders after every expense, interest and tax.

Celularity's net income for the twelve months ending Jun 30, 2026 was -$45.86M. For fiscal 2025 it was -$91.72M. The highest annual figure on record is $14.19M in fiscal 2022.

Annual net income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$91.72M–
FY2024Dec 31, 2024-$57.89M–
FY2023Dec 31, 2023-$196.30M-1483.1%
FY2022Dec 31, 2022$14.19M–
FY2021Dec 31, 2021-$100.12M–
FY2020Dec 31, 2020-$208.23M-3642.1%
FY2019Dec 31, 2019$5.88M–

Quarterly net income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$706.00K–
Q1 FY2026Mar 31, 2026$874.00K–
Q4 FY2025Dec 31, 2025-$24.36M–
Q3 FY2025Sep 30, 2025-$23.08M–
Q2 FY2025Jun 30, 2025-$24.52M–
Q1 FY2025Mar 31, 2025-$19.75M–
Q4 FY2024Dec 31, 2024-$13.29M-239.2%
Q3 FY2024Sep 30, 2024-$16.10M–
Q2 FY2024Jun 30, 2024-$6.49M–
Q1 FY2024Mar 31, 2024-$22.01M–
Q4 FY2023Dec 31, 2023$9.55M-60.9%
Q3 FY2023Sep 30, 2023-$93.88M-2056.2%
Q2 FY2023Jun 30, 2023-$47.95M-200.3%
Q1 FY2023Mar 31, 2023-$64.02M–
Q4 FY2022Dec 31, 2022$24.43M–
Q3 FY2022Sep 30, 2022$4.80M-90.4%
Q2 FY2022Jun 30, 2022$47.83M–
Q1 FY2022Mar 31, 2022-$62.87M–
Q4 FY2021Dec 31, 2021-$4.04M-203.3%
Q3 FY2021Sep 30, 2021$49.94M–
Q2 FY2021Jun 30, 2021-$64.48M–
Q1 FY2021Mar 31, 2021-$81.54M-1380.4%
Q4 FY2020Dec 31, 2020$3.91M-5.2%
Q3 FY2020Sep 30, 2020-$46.33M-4231.9%
Q2 FY2020Jun 30, 2020-$12.11M-2008.1%
Q1 FY2020Mar 31, 2020$6.37M–
Q4 FY2019Dec 31, 2019$4.12M–
Q3 FY2019Sep 30, 2019$1.12M–
Q2 FY2019Jun 30, 2019$634.66K–
Q1 FY2019Mar 31, 2019-$121–

More Celularity figures

See a number that looks wrong?